Generics industry complains of EFPIA 'misinformation' on counterfeiting
This article was originally published in Scrip
In a 10 July letter to the European Commission, the European Generic medicines Association (EGA) has drawn attention to what it calls 'misinformation' emanating from the R&D-based industry association, the European Federation of Pharmaceutical Industries and Associations (EFPIA), on counterfeiting in the generics sector.
You may also be interested in...
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.
The pharma and biotech industries have welcomed Australia’s coronavirus recovery budget, which also sets aside funding for research into COVID-19 vaccines and makes positive changes to R&D tax incentives.